Lexicon Genetics to Present at Banc of America Securities Healthcare Conference
11 May 2005
Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the Banc of America Securities Healthcare Conference at The Four Seasons Hotel in Las Vegas, Nevada on Tuesday, May 17, 2005 at 1:20 p.m. Pacific Time. Dr. Sands will provide an overview of Lexicon and discuss its drug discovery and development programs and collaborations.
A live webcast of Dr. Sands' presentation may be accessed on Lexicon's corporate website at http://www.lexicon-genetics.com . An archived version of the webcast will be available on the website through May 25, 2005.
About Lexicon Genetics
Lexicon Genetics is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The Company has advanced knockout- validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries. Additional information about Lexicon is available through its corporate website, http://www.lexicon-genetics.com .
Safe Harbor Statement
This press release contains "forward-looking statements," including statements about Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. These forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical development of its drug candidates and advance such candidates into clinical development, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as those relating to manufacturing, the regulatory process, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Business - Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2004, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
--------------------------------------------------------------------------------
Source: Lexicon Genetics Incorporated
Source: PR Newswire
All trademarks and copyrighted information contained herein are the property of their respective owners.
Related Articles
|
